Evopep-D semaglutide

Evopep-D semaglutide is an oral formulation of the GLP-1 receptor agonist semaglutide, developed by Bhami's Research Laboratory using their proprietary Evopep platform. The Evopep platform is designed to enable the oral delivery of biologics, such as peptides and proteins, which typically have poor oral bioavailability. In preclinical pig studies, this formulation demonstrated a bioavailability of approximately 10–15%. As a GLP-1 receptor agonist, it mimics the action of the endogenous incretin hormone to stimulate insulin secretion, inhibit glucagon release, and reduce appetite, making it a candidate for the treatment of type 2 diabetes and obesity.

Other names

Semaglutide (Evopep-D formulation)oral semaglutide (BRL)